1
|
Ochman B, Limanówka P, Mielcarska S, Kula A, Dawidowicz M, Wagner W, Hudy D, Szrot M, Piecuch JZ, Piecuch J, Czuba Z, Świętochowska E. Associations of SEMA7A, SEMA4D, ADAMTS10, and ADAM8 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, Microsatellite Instability Status, and Cytokine Expression in Colorectal Cancer Tissue. Curr Issues Mol Biol 2024; 46:10218-10248. [PMID: 39329961 DOI: 10.3390/cimb46090609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2024] [Revised: 09/11/2024] [Accepted: 09/13/2024] [Indexed: 09/28/2024] Open
Abstract
Semaphorins (SEMAs), ADAM, and ADAMTS family members are implicated in various cancer progression events within the tumor microenvironment across different cancers. In this study, we aimed to evaluate the expression of SEMA7A, SEMA4D, ADAM8, and ADAMTS10 in colorectal cancer (CRC) in relation to the mutational landscape of KRAS, NRAS, BRAF, PIK3CA, and AKT genes, microsatellite instability (MSI) status, and clinicopathological features. We also examined the associations between the expression of these proteins and selected cytokines, chemokines, and growth factors, assessed using a multiplex assay. Protein concentrations were quantified using ELISA in CRC tumors and tumor-free surgical margin tissue homogenates. Gene mutations were evaluated via RT-PCR, and MSI status was determined using immunohistochemistry (IHC). GSEA and statistical analyses were performed using R Studio. We observed a significantly elevated expression of SEMA7A in BRAF-mutant CRC tumors and an overexpression of ADAM8 in KRAS 12/13-mutant tumors. The expression of ADAMTS10 was decreased in PIK3CA-mutant CRC tumors. No significant differences in the expression of the examined proteins were observed based on MSI status. The SEMA7A and SEMA4D expressions were correlated with the expression of numerous cytokines associated with various immune processes. The potential immunomodulatory functions of these molecules and their suitability as therapeutic targets require further investigation.
Collapse
Affiliation(s)
- Błażej Ochman
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-808 Zabrze, Poland
| | - Piotr Limanówka
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-808 Zabrze, Poland
| | - Sylwia Mielcarska
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-808 Zabrze, Poland
| | - Agnieszka Kula
- Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Katowice, Poland
| | - Miriam Dawidowicz
- Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Katowice, Poland
| | - Wiktor Wagner
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-808 Zabrze, Poland
| | - Dorota Hudy
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-808 Zabrze, Poland
| | - Monika Szrot
- Department of General and Bariatric Surgery and Emergency Medicine in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 10 Marii Curie-Skłodowskiej, 41-800 Zabrze, Poland
| | - Jerzy Zbigniew Piecuch
- Department of General and Bariatric Surgery and Emergency Medicine in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 10 Marii Curie-Skłodowskiej, 41-800 Zabrze, Poland
| | - Jerzy Piecuch
- Department of General and Bariatric Surgery and Emergency Medicine in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 10 Marii Curie-Skłodowskiej, 41-800 Zabrze, Poland
| | - Zenon Czuba
- Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-808 Zabrze, Poland
| | - Elżbieta Świętochowska
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-808 Zabrze, Poland
| |
Collapse
|
2
|
Huang J, Zhao C, Zhang S. Semaphorin 7A promotes endothelial permeability and inflammation via plexin C1 and integrin β1 in Kawasaki disease. BMC Pediatr 2024; 24:285. [PMID: 38678170 PMCID: PMC11055240 DOI: 10.1186/s12887-024-04766-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 04/16/2024] [Indexed: 04/29/2024] Open
Abstract
BACKGROUND Kawasaki disease (KD) is a pediatric systemic vasculitis characterized by endothelial cell dysfunction. Semaphorin 7A (Sema7A) has been reported to regulate endothelial phenotypes associated with cardiovascular diseases, while its role in KD remains unknown. This study aims to investigate the effect of Sema7A on endothelial permeability and inflammatory response in KD conditions. METHODS Blood samples were collected from 68 KD patients and 25 healthy children (HC). The levels of Sema7A and A Disintegrin and Metalloprotease 17 (ADAM17) in serum were measured by enzyme-linked immunosorbent assay (ELISA), and Sema7A expression in blood cells was analyzed by flow cytometry. Ex vivo monocytes were used for Sema7A shedding assays. In vitro human coronary artery endothelial cells (HCAECs) were cultured in KD sera and stimulated with Sema7A, and TNF-α, IL-1β, IL-6, and IL-18 of HCAECs were measured by ELISA and qRT-PCR. HCAECs monolayer permeability was measured by FITC-dextran. RESULTS The serum level of Sema7A was significantly higher in KD patients than in HC and correlated with disease severity. Monocytes were identified as one of the source of elevated serum Sema7A, which implicates a process of ADAM17-dependent shedding. Sera from KD patients induced upregulation of plexin C1 and integrin β1 in HCAECs compared to sera from HC. Sema7A mediated the proinflammatory cytokine production of HCAECs in an integrin β1-dependent manner, while both plexin C1 and integrin β1 contributed to Sema7A-induced HCAEC hyperpermeability. CONCLUSIONS Sema7A is involved in the progression of KD vasculitis by promoting endothelial permeability and inflammation through a plexin C1 and integrin β1-dependent pathway. Sema7A may serve as a potential biomarker and therapeutic target in the prognosis and treatment of KD.
Collapse
Affiliation(s)
- Junhua Huang
- School of Medical Technology, Xi'an Medical University, Xi'an, 710021, Shaanxi Province, China
| | - Chuanmei Zhao
- Department of Clinical Laboratory, Xi'an Children's Hospital, Xi'an, 710003, Shaanxi Province, China
| | - Shuwan Zhang
- Department of Clinical Laboratory, Xi'an Children's Hospital, Xi'an, 710003, Shaanxi Province, China.
| |
Collapse
|
3
|
Hu P, Miller AE, Yeh CR, Bingham GC, Civelek M, Barker TH. SEMA7a primes integrin α5β1 engagement instructing fibroblast mechanotransduction, phenotype and transcriptional programming. Matrix Biol 2023; 121:179-193. [PMID: 37422024 DOI: 10.1016/j.matbio.2023.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Revised: 06/15/2023] [Accepted: 06/26/2023] [Indexed: 07/10/2023]
Abstract
Integrins are cellular receptors that bind the extracellular matrix (ECM) and facilitate the transduction of biochemical and biophysical microenvironment cues into cellular responses. Upon engaging the ECM, integrin heterodimers must rapidly strengthen their binding with the ECM, resulting in the assembly of force-resistant and force-sensitive integrin associated complexes (IACs). The IACs constitute an essential apparatus for downstream signaling and fibroblast phenotypes. During wound healing, integrin signaling is essential for fibroblast motility, proliferation, ECM reorganization and, ultimately, restoration of tissue homeostasis. Semaphorin 7A (SEMA7a) has been previously implicated in post-injury inflammation and tissue fibrosis, yet little is known about SEMA7a's role in directing stromal cell, particularly fibroblast, behaviors. We demonstrate that SEMA7a regulates integrin signaling through cis-coupling with active integrin α5β1 on the plasma membrane, enabling rapid integrin adhesion strengthening to fibronectin (Fn) and normal downstream mechanotransduction. This molecular function of SEMA7a potently regulates fibroblast adhesive, cytoskeletal, and migratory phenotype with strong evidence of downstream alterations in chromatin structure resulting in global transcriptomic reprogramming such that loss of SEMA7a expression is sufficient to impair the normal migratory and ECM assembly phenotype of fibroblasts resulting in significantly delayed tissue repair in vivo.
Collapse
Affiliation(s)
- Ping Hu
- Department of Biomedical Engineering, Schools of Engineering and Medicine, Charlottesville, VA 22908, USA
| | - Andrew E Miller
- Department of Biomedical Engineering, Schools of Engineering and Medicine, Charlottesville, VA 22908, USA
| | - Chiuan-Ren Yeh
- Department of Biomedical Engineering, Schools of Engineering and Medicine, Charlottesville, VA 22908, USA
| | - Grace C Bingham
- Department of Biomedical Engineering, Schools of Engineering and Medicine, Charlottesville, VA 22908, USA
| | - Mete Civelek
- Department of Biomedical Engineering, Schools of Engineering and Medicine, Charlottesville, VA 22908, USA; Center for Public Health Genomics, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
| | - Thomas H Barker
- Department of Biomedical Engineering, Schools of Engineering and Medicine, Charlottesville, VA 22908, USA.
| |
Collapse
|
4
|
Lu Q, Liu Z, Zhao L, Xu L, Liu C, Li L, Cao Y, Li F, Wu L, Wang L, Chen T, You T, Ren L, Wang G, Tang C, Zhu L. Sema7A protects against high-fat diet-induced obesity and hepatic steatosis by regulating adipo/lipogenesis. Mol Metab 2023; 70:101698. [PMID: 36842496 PMCID: PMC10009717 DOI: 10.1016/j.molmet.2023.101698] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2023] [Revised: 02/20/2023] [Accepted: 02/20/2023] [Indexed: 02/28/2023] Open
Abstract
OBJECTIVE Obesity and related diseases are becoming a growing risk for public health around the world due to the westernized lifestyle. Sema7A, an axonal guidance molecule, has been known to play a role in neurite growth, bone formation, and immune regulation. Whether Sema7A participates in obesity and metabolic diseases is unknown. As several SNPs in SEMA7A and its receptors were found to correlate with BMI and metabolic parameters in the human population, we investigated the potential role of Sema7A in obesity and hepatic steatosis. METHODS GWAS and GEPIA database was used to analyze SNPs in SEMA7A and the correlation of Sema7A expression with lipid metabolism related genes. Sema7A-/- mice and recombinant Sema7A (rSema7A) were used to study the role of Sema7A in HFD-induced obesity and hepatic steatosis. Adipose tissue-derived mesenchymal stem cells (ADSCs) were used to examine the role of Sema7A in adipogenesis, lipogenesis and downstream signaling. RESULTS Deletion of Sema7A aggravated HFD-induced obesity. Sema7A deletion enhanced adipogenesis in both subcutaneous and visceral ADSCs, while the addition of rSema7A inhibited adipogenesis of ADSCs and lipogenesis of differentiated mature adipocytes. Sema7A inhibits adipo/lipogenesis potentially through its receptor integrin β1 and downstream FAK signaling. Importantly, administration of rSema7A had protective effects against diet-induced obesity in mice. In addition, deletion of Sema7A led to increased hepatic steatosis and insulin resistance in mice. CONCLUSIONS Our findings reveal a novel inhibitory role of Sema7A in obesity and hepatic steatosis, providing a potential new therapeutic target for obesity and metabolic diseases.
Collapse
Affiliation(s)
- Qiongyu Lu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Ziting Liu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Luyao Zhao
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Linru Xu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Chu Liu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Ling Li
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Yiren Cao
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Fengchan Li
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Lili Wu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Lei Wang
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Ting Chen
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Tao You
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Lijie Ren
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Guixue Wang
- JinFeng Laboratory, Chongqing, China; Key Laboratory of Biorheological and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, China
| | - Chaojun Tang
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China; National Clinical Research Center for Hematologic Diseases at the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; The Ninth Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China; JinFeng Laboratory, Chongqing, China.
| | - Li Zhu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China; National Clinical Research Center for Hematologic Diseases at the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; The Ninth Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China; JinFeng Laboratory, Chongqing, China.
| |
Collapse
|
5
|
Wang Y, Li C, Qi X, Yao Y, Zhang L, Zhang G, Xie L, Wang Q, Zhu W, Guo X. A Comprehensive Prognostic Analysis of Tumor-Related Blood Group Antigens in Pan-Cancers Suggests That SEMA7A as a Novel Biomarker in Kidney Renal Clear Cell Carcinoma. Int J Mol Sci 2022; 23:ijms23158799. [PMID: 35955933 PMCID: PMC9369114 DOI: 10.3390/ijms23158799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 07/30/2022] [Accepted: 08/02/2022] [Indexed: 11/16/2022] Open
Abstract
Blood group antigen is a class of heritable antigenic substances present on the erythrocyte membrane. However, the role of blood group antigens in cancer prognosis is still largely unclear. In this study, we investigated the expression of 33 blood group antigen genes and their association with the prognosis of 30 types of cancers in 31,870 tumor tissue samples. Our results revealed that blood group antigens are abnormally expressed in a variety of cancers. The high expression of these antigen genes was mainly related to the activation of the epithelial-mesenchymal transition (EMT) pathway. High expression of seven antigen genes, i.e., FUT7, AQP1, P1, C4A, AQP3, KEL and DARC, were significantly associated with good OS (Overall Survival) in six types of cancers, while ten genes, i.e., AQP1, P1, C4A, AQP3, BSG, CD44, CD151, LU, FUT2, and SEMA7A, were associated with poor OS in three types of cancers. Kidney renal clear cell carcinoma (KIRC) is associated with the largest number (14 genes) of prognostic antigen genes, i.e., CD44, CD151, SEMA7A, FUT7, CR1, AQP1, GYPA, FUT3, FUT6, FUT1, SLC14A1, ERMAP, C4A, and B3GALT3. High expression of SEMA7A gene was significantly correlated with a poor prognosis of KIRC in this analysis but has not been reported previously. SEMA7A might be a putative biomarker for poor prognosis in KIRC. In conclusion, our analysis indicates that blood group antigens may play functional important roles in tumorigenesis, progression, and especially prognosis. These results provide data to support prognostic marker development and future clinical management.
Collapse
Affiliation(s)
- Yange Wang
- Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng 475004, China
| | - Chenyang Li
- Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng 475004, China
| | - Xinlei Qi
- Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng 475004, China
| | - Yafei Yao
- Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng 475004, China
| | - Lu Zhang
- Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng 475004, China
| | - Guosen Zhang
- Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng 475004, China
| | - Longxiang Xie
- Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng 475004, China
| | - Qiang Wang
- Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng 475004, China
| | - Wan Zhu
- Department of Anesthesia, Stanford University, Stanford, CA 94305, USA
| | - Xiangqian Guo
- Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng 475004, China
- Correspondence:
| |
Collapse
|
6
|
A Genome-Wide Association Study of Age-Related Hearing Impairment in Middle- and Old-Aged Chinese Twins. BIOMED RESEARCH INTERNATIONAL 2021; 2021:3629624. [PMID: 34337005 PMCID: PMC8314043 DOI: 10.1155/2021/3629624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 06/17/2021] [Accepted: 07/03/2021] [Indexed: 11/17/2022]
Abstract
Background Age-related hearing impairment (ARHI) is considered an unpreventable disorder. We aimed to detect specific genetic variants that are potentially related to ARHI via genome-wide association study (GWAS). Methods A sample of 131 dizygotic twins was genotyped for single-nucleotide polymorphism- (SNP-) based GWAS. Gene-based test was performed using VEGAS2. Pathway enrichment analysis was conducted by PASCAL. Results The twins are with a median age of 49 years, of which 128 were females and 134 were males. rs6633657 was the only SNP that reached the genome-wide significance level for better ear hearing level (BEHL) at 2.0 kHz (P = 1.19 × 10-8). Totally, 9, 10, 42, 7, 17, and 5 SNPs were suggestive evidence level for (P < 1 × 10-5) BEHLs at 0.5, 1.0, 2.0, 4.0, and 8.0 kHz and pure tone average (PTA), respectively. Several promising genetic regions in chromosomes (near the C20orf196, AQPEP, UBQLN3, OR51B5, OR51I2, OR52D1, GLTP, GIT2, and PARK2) nominally associated with ARHI were identified. Gene-based analysis revealed 165, 173, 77, 178, 170, and 145 genes nominally associated with BEHLs at 0.5, 1.0, 2.0, 4.0, and 8.0 kHz and PTA, respectively (P < 0.05). For BEHLs at 0.5, 1.0, and 2.0 kHz, the main enriched pathways were phosphatidylinositol signaling system, regulation of ornithine decarboxylase, eukaryotic translation initiation factor (EIF) pathway, amine compound solute carrier (SLC) transporters, synthesis of phosphoinositides (PIPS) at the plasma membrane, and phosphatidylinositols (PI) metabolism. Conclusions The genetic variations reported herein are significantly involved in functional genes and regulatory domains that mediate ARHI pathogenesis. These findings provide clues for the further unraveling of the molecular physiology of hearing functions and identifying novel diagnostic biomarkers and therapeutic targets of ARHI.
Collapse
|
7
|
Borges VF, Hu J, Young C, Maggard J, Parris HJ, Gao D, Lyons TR. Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ Breast Cancer 2020; 6:56. [PMID: 33088913 PMCID: PMC7572422 DOI: 10.1038/s41523-020-00198-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 09/17/2020] [Indexed: 12/11/2022] Open
Abstract
Breast cancer is a global health threat and cases diagnosed in women during the years after childbirth, or postpartum breast cancers (PPBCs), have high risk for metastasis. In preclinical murine models, semaphorin 7a (SEMA7A) drives the metastatic potential of postpartum mammary tumors. Thus, we hypothesize that SEMA7A may drive metastasis of PPBC in women. We report that SEMA7A protein expression is increased in PPBCs compared to their nulliparous counterparts in our University of Colorado cohort. Additionally, tumors from PPBC patients with involved lymph nodes and lymphovascular invasion were higher on average suggesting a potential role for SEMA7A as a prognostic biomarker. Consistent with this hypothesis we identify a level of SEMA7A expression in tumors that can predict for recurrence. We propose SEMA7A as a potential biomarker and therapeutic target for PPBC patients, who currently lack strong predictors of outcome and unique targeted therapy options.
Collapse
Affiliation(s)
- Virginia F. Borges
- Young Women’s Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO USA
- Division of Medical Oncology, University of Colorado, Anschutz Medical Center, Aurora, CO USA
| | - Junxiao Hu
- Department of Pediatrics, School of Medicine, and Dept of Biostatistics, University of Colorado School of Public Health, Aurora, CO USA
| | - Chloe Young
- Division of Medical Oncology, University of Colorado, Anschutz Medical Center, Aurora, CO USA
| | - Jaron Maggard
- Division of Medical Oncology, University of Colorado, Anschutz Medical Center, Aurora, CO USA
| | - Hannah J. Parris
- Young Women’s Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO USA
- Department of Epidemiology, University of Colorado School of Public Health, Aurora, CO USA
| | - Dexiang Gao
- Department of Pediatrics, School of Medicine, and Dept of Biostatistics, University of Colorado School of Public Health, Aurora, CO USA
| | - Traci R. Lyons
- Young Women’s Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO USA
- Division of Medical Oncology, University of Colorado, Anschutz Medical Center, Aurora, CO USA
| |
Collapse
|
8
|
Li D, Peng H, Qu L, Sommar P, Wang A, Chu T, Li X, Bi X, Liu Q, Gallais Sérézal I, Rollman O, Lohcharoenkal W, Zheng X, Eliasson Angelstig S, Grünler J, Pivarcsi A, Sonkoly E, Catrina SB, Xiao C, Ståhle M, Mi QS, Zhou L, Xu Landén N. miR-19a/b and miR-20a Promote Wound Healing by Regulating the Inflammatory Response of Keratinocytes. J Invest Dermatol 2020; 141:659-671. [PMID: 32949564 DOI: 10.1016/j.jid.2020.06.037] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 06/10/2020] [Accepted: 06/29/2020] [Indexed: 12/14/2022]
Abstract
Persistent and impaired inflammation impedes tissue healing and is a characteristic of chronic wounds. A better understanding of the mechanisms controlling wound inflammation is needed. In this study, we show that in human wound-edge keratinocytes, the expressions of microRNA (miR)-17, miR-18a, miR-19a, miR-19b, and miR-20a, which all belong to the miR-17∼92 cluster, are upregulated during wound repair. However, their levels are lower in chronic ulcers than in acute wounds at the proliferative phase. Conditional knockout of miR-17∼92 in keratinocytes as well as injection of miR-19a/b and miR-20a antisense inhibitors into wound edges enhanced inflammation and delayed wound closure in mice. In contrast, conditional overexpression of the miR-17∼92 cluster or miR-19b alone in mice keratinocytes accelerated wound closure in vivo. Mechanistically, miR-19a/b and miR-20a decreased TLR3-mediated NF-κB activation by targeting SHCBP1 and SEMA7A, respectively, reducing the production of inflammatory chemokines and cytokines by keratinocytes. Thus, miR-19a/b and miR-20a being crucial regulators of wound inflammation, the lack thereof may contribute to sustained inflammation and impaired healing in chronic wounds. In line with this, we show that a combinatory treatment with miR-19b and miR-20a improved wound healing in a mouse model of type 2 diabetes.
Collapse
Affiliation(s)
- Dongqing Li
- Dermatology and Venereology Division, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden
| | - Hongmei Peng
- Department of Dermatology, Center for Cutaneous Biology and Immunology Research, Henry Ford Health System, Detroit, Michigan, USA; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA; MirnaTech International, LLC, Detroit, Michigan, USA
| | - Le Qu
- Department of Dermatology, Center for Cutaneous Biology and Immunology Research, Henry Ford Health System, Detroit, Michigan, USA; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Pehr Sommar
- Department of Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden
| | - Aoxue Wang
- Department of Dermatology, The Second Hospital of Dalian Medical University, Dalian, China
| | - Tongbin Chu
- Department of Wound Repair, The Second Hospital of Dalian Medical University, Dalian, China
| | - Xi Li
- Dermatology and Venereology Division, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden
| | - Xinling Bi
- Department of Dermatology, Center for Cutaneous Biology and Immunology Research, Henry Ford Health System, Detroit, Michigan, USA; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Queping Liu
- Department of Dermatology, Center for Cutaneous Biology and Immunology Research, Henry Ford Health System, Detroit, Michigan, USA; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Irène Gallais Sérézal
- Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden; Department of Medical Genetics, Hôpital Henri Mondor, APHP, Créteil, France
| | - Ola Rollman
- Department of Dermatology, Academic University Hospital, Uppsala, Sweden
| | - Warangkana Lohcharoenkal
- Dermatology and Venereology Division, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden
| | - Xiaowei Zheng
- Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden
| | | | - Jacob Grünler
- Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden
| | - Andor Pivarcsi
- Dermatology and Venereology Division, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medical Biochemistry and Microbiology (IMBIM), Uppsala University, Uppsala, Sweden
| | - Enikö Sonkoly
- Dermatology and Venereology Division, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden
| | - Sergiu-Bogdan Catrina
- Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden; Centrum for Diabetes, Academic Specialist Centrum, Stockholm, Sweden
| | - Changchun Xiao
- Department of Immunology and Microbiology, The Scripps Research Institute, San Diego, California, USA
| | - Mona Ståhle
- Dermatology and Venereology Division, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden
| | - Qing-Sheng Mi
- Department of Dermatology, Center for Cutaneous Biology and Immunology Research, Henry Ford Health System, Detroit, Michigan, USA; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Li Zhou
- Department of Dermatology, Center for Cutaneous Biology and Immunology Research, Henry Ford Health System, Detroit, Michigan, USA; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Ning Xu Landén
- Dermatology and Venereology Division, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden; Ming Wai Lau Centre for Reparative Medicine, Stockholm node, Karolinska Institute, Stockholm, Sweden.
| |
Collapse
|
9
|
Elder AM, Stoller AR, Black SA, Lyons TR. Macphatics and PoEMs in Postpartum Mammary Development and Tumor Progression. J Mammary Gland Biol Neoplasia 2020; 25:103-113. [PMID: 32535810 PMCID: PMC7395889 DOI: 10.1007/s10911-020-09451-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Accepted: 05/29/2020] [Indexed: 12/13/2022] Open
Abstract
Postpartum mammary gland involution is a mammalian tissue remodeling event that occurs after pregnancy and lactation to return the gland to the pre-pregnant state. This event is characterized by apoptosis and lysosomal-mediated cell death of the majority of the lactational mammary epithelium, followed by remodeling of the extracellular matrix, influx of immune cell populations (in particular, T helper cells, monocytes, and macrophages), and neo-lymphangiogenesis. This postpartum environment has been shown to be promotional for tumor growth and metastases and may partially account for why women diagnosed with breast cancer during the postpartum period or within 5 years of last childbirth have an increased risk of developing metastases when compared to their nulliparous counterparts. The lymphatics and macrophages present during mammary gland involution have been implicated in promoting the observed growth and metastasis. Of importance are the macrophages, which are of the "M2" phenotype and are known to create a pro-tumor microenvironment. In this report, we describe a subset of postpartum macrophages that express lymphatic proteins (PoEMs) and directly interact with lymphatic vessels to form chimeric vessels or "macphatics". Additionally, these PoEMs are very similar to tumor-associated macrophages that also express lymphatic proteins and are present at the sites of lymphatic vessels where tumors escape the tissue and enter the lymphatic vasculature. Further characterizing these PoEMs may offer insight in preventing lymphatic metastasis of breast cancer, as well as provide information for how developmental programming of lymphatic endothelial cells and macrophages can contribute to different disease progression.
Collapse
Affiliation(s)
- Alan M Elder
- Young Women's Breast Cancer Translational Program, Division of Medical Oncology, University of Colorado Cancer Center, 12801 E 17th Ave, RC1 South, Mailstop 8117, Aurora, CO, 80045, USA
- Division of Medical Oncology, Anschutz Medical Center, University of Colorado, Aurora, CO, USA
- Graduate Program in Cancer Biology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Alexander R Stoller
- Young Women's Breast Cancer Translational Program, Division of Medical Oncology, University of Colorado Cancer Center, 12801 E 17th Ave, RC1 South, Mailstop 8117, Aurora, CO, 80045, USA
- Division of Medical Oncology, Anschutz Medical Center, University of Colorado, Aurora, CO, USA
| | - Sarah A Black
- University of Colorado School of Medicine, Aurora, CO, USA
| | - Traci R Lyons
- Young Women's Breast Cancer Translational Program, Division of Medical Oncology, University of Colorado Cancer Center, 12801 E 17th Ave, RC1 South, Mailstop 8117, Aurora, CO, 80045, USA.
- Division of Medical Oncology, Anschutz Medical Center, University of Colorado, Aurora, CO, USA.
- Graduate Program in Cancer Biology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
| |
Collapse
|
10
|
Hu S, Zhu L. Semaphorins and Their Receptors: From Axonal Guidance to Atherosclerosis. Front Physiol 2018; 9:1236. [PMID: 30405423 PMCID: PMC6196129 DOI: 10.3389/fphys.2018.01236] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2018] [Accepted: 08/15/2018] [Indexed: 12/24/2022] Open
Abstract
Semaphorins are a large family of secreted, transmembrane, or GPI-anchored proteins initially identified as axon guidance cues signaling through their receptors, neuropilins, and plexins. Emerging evidence suggests that beyond the guidance, they also function in a broad spectrum of pathophysiological conditions, including atherosclerosis, a vascular inflammatory disease. Particular semaphorin members have been demonstrated to participate in atherosclerosis via eliciting endothelial dysfunction, leukocyte infiltration, monocyte-macrophage retention, platelet hyperreactivity, and neovascularization. In this review, we focus on the role of those semaphorin family members in the development of atherosclerosis and highlight the mechanistic relevance of semaphorins to atherogenesis.
Collapse
Affiliation(s)
- Shuhong Hu
- Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.,State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China
| | - Li Zhu
- Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.,State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China
| |
Collapse
|
11
|
Lee Y, Blount KL, Dai F, Thompson S, Scher JK, Bitterman S, Droher M, Herzog EL, Moeckel G, Karihaloo A, Dahl NK. Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment. Clin Exp Nephrol 2018; 22:906-916. [PMID: 29453607 DOI: 10.1007/s10157-018-1542-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2017] [Accepted: 02/07/2018] [Indexed: 12/23/2022]
Abstract
BACKGROUND Semaphorin 7A (SEMA7A) is an immunomodulating protein implicated in lung and liver fibrosis. In autosomal-dominant polycystic kidney disease (ADPKD), the progressive expansion of renal cysts, inflammation, and subsequent renal fibrosis leads to end-stage renal disease (ESRD). SEMA7A may play a role in renal fibrosis and in ADPKD. METHODS We evaluated Sema7a in a mouse model of renal fibrosis and determined the expression of SEMA7A in human ADPKD kidney. We analyzed SEMA7A expression on peripheral blood mononuclear cells (PBMCs), including CD45+ (leukocyte), CD14+(monocyte), CD4+ (T lymphocytes) and CD4+Foxp3+CD25+ [regulatory T lymphocytes (Tregs)] from 90 ADPKD patients (11 tolvaptan treated and 79 tolvaptan naïve), and 21 healthy volunteers, using a Fluorescence-Activated Cell Sorting (FACS). RESULTS Sema7a is required for renal fibrosis. SEMA7A shows robust expression in ADPKD kidneys, localizing to cysts derived from distal tubules. SEMA7A is higher in circulating monocytes, but unchanged in CD4+ lymphocytes in ADPKD patients. The SEMA7A increase was detected early (stage 1 CKD) and seemed more prominent in patients with smaller kidneys (p = 0.09). Compared to tolvaptan-naïve ADPKD patients, those treated with tolvaptan showed reduced SEMA7A expression on monocytes, T lymphocytes, and Tregs, although the number of PBMCs was unchanged. After 1 month of tolvaptan treatment, SEMA7A expression on Tregs decreased. CONCLUSIONS SEMA7A shows potential as both a therapeutic target in mammalian kidney fibrosis and as a marker of inflammation in ADPKD patients. SEMA7A expression was lower after tolvaptan treatment, which may reflect drug efficacy.
Collapse
Affiliation(s)
- Yashang Lee
- Section of Nephrology, Yale University School of Medicine, New Haven, CT, 06510, USA
| | | | - Feng Dai
- Department of Biostatics, Yale University School of Public Health, 300 George Street, New Haven, CT, 06511, USA
| | - Siobhan Thompson
- Section of Nephrology, Yale University School of Medicine, New Haven, CT, 06510, USA
| | | | - Sherrie Bitterman
- Section of Nephrology, Yale University School of Medicine, New Haven, CT, 06510, USA
| | - Madeline Droher
- Section of Nephrology, Yale University School of Medicine, New Haven, CT, 06510, USA
| | - Erica L Herzog
- Section of Nephrology, Yale University School of Medicine, New Haven, CT, 06510, USA
| | - Gilbert Moeckel
- Section of Nephrology, Yale University School of Medicine, New Haven, CT, 06510, USA
| | - Anil Karihaloo
- Section of Nephrology, Yale University School of Medicine, New Haven, CT, 06510, USA.
| | - Neera K Dahl
- Section of Nephrology, Yale University School of Medicine, New Haven, CT, 06510, USA.
| |
Collapse
|
12
|
Wu X, Meng Y, Wang C, Yue Y, Dong C, Xiong S. Semaphorin7A aggravates coxsackievirusB3-induced viral myocarditis by increasing α1β1-integrin macrophages and subsequent enhanced inflammatory response. J Mol Cell Cardiol 2018; 114:48-57. [DOI: 10.1016/j.yjmcc.2017.11.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Revised: 11/01/2017] [Accepted: 11/02/2017] [Indexed: 12/22/2022]
|
13
|
Hu S, Liu Y, You T, Heath J, Xu L, Zheng X, Wang A, Wang Y, Li F, Yang F, Cao Y, Zhang H, van Gils JM, van Zonneveld AJ, Jo H, Wu Q, Zhang Y, Tang C, Zhu L. Vascular Semaphorin 7A Upregulation by Disturbed Flow Promotes Atherosclerosis Through Endothelial β1 Integrin. Arterioscler Thromb Vasc Biol 2017; 38:335-343. [PMID: 29269512 DOI: 10.1161/atvbaha.117.310491] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Accepted: 12/06/2017] [Indexed: 12/22/2022]
Abstract
OBJECTIVE Accumulating evidence suggests a role of semaphorins in vascular homeostasis. Here, we investigate the role of Sema7A (semaphorin 7A) in atherosclerosis and its underlying mechanism. APPROACH AND RESULTS Using genetically engineered Sema7A-/-ApoE-/- mice, we showed that deletion of Sema7A attenuates atherosclerotic plaque formation primarily in the aorta of ApoE-/- mice on a high-fat diet. A higher level of Sema7A in the atheroprone lesser curvature suggests a correlation of Sema7A with disturbed flow. This notion is supported by elevated Sema7A expression in human umbilical venous endothelial cells either subjected to oscillatory shear stress or treated with the PKA (protein kinase A)/CREB (cAMP response element-binding protein) inhibitor H89 (N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide·2HCl hydrate). Further studies using the partial carotid artery ligation model showed that disturbed flow in the left carotid artery of Sema7A+/+ApoE-/- mice promoted the expression of endothelial Sema7A and cell adhesion molecules, leukocyte adhesion, and plaque formation, whereas such changes were attenuated in Sema7A-/-ApoE-/- mice. Further studies showed that blockage of β1 integrin, a known Sema7A receptor, or inhibition of FAK (focal adhesion kinase), MEK1/2 (mitogen-activated protein kinase kinase 1/2), or NF-κB (nuclear factor-κB) significantly reduced the expression of cell adhesion molecules and THP-1 (human acute monocytic leukemia cell line) monocyte adhesion in Sema7A-overexpressing human umbilical venous endothelial cells. Studies using chimeric mice suggest that vascular, most likely endothelial, Sema7A plays a major role in atherogenesis. CONCLUSIONS Our findings indicate a significant role of Sema7A in atherosclerosis by mediating endothelial dysfunction in a β1 integrin-dependent manner.
Collapse
Affiliation(s)
- Shuhong Hu
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Yifei Liu
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Tao You
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Jack Heath
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Linru Xu
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Xiaowei Zheng
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Aili Wang
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Yinyan Wang
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Fengchan Li
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Fei Yang
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Yiren Cao
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Huayu Zhang
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Janine M van Gils
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Anton Jan van Zonneveld
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Hanjoong Jo
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Qingyu Wu
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Yonghong Zhang
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.)
| | - Chaojun Tang
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.).
| | - Li Zhu
- From the Cyrus Tang Hematology Center (S.H., Y.L., T.Y., L.X., Y.W., F.L., F.Y., Y.C., Q.W., C.T., L.Z.), Department of Epidemiology, School of Public Health (X.Z., A.W., Y.Z.), Collaborative Innovation Center of Hematology of Jiangsu Province (S.H., Y.L., T.Y., Q.W., C.T., L.Z.), and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases (X.Z., A.W., Q.W., Y.Z.), Soochow University, Suzhou, China; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta (J.H., H.J.); Einthoven Laboratory for Experimental Vascular Medicine, Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center, the Netherlands (H.Z., J.M.v.G., A.J.v.Z.); and Department of Molecular Cardiology, Cleveland Clinic, OH (Q.W.).
| |
Collapse
|
14
|
Garcia-Areas R, Libreros S, Simoes M, Castro-Silva C, Gazaniga N, Amat S, Jaczewska J, Keating P, Schilling K, Brito M, Wojcikiewicz EP, Iragavarpu-Charyulu V. Suppression of tumor-derived Semaphorin 7A and genetic ablation of host-derived Semaphorin 7A impairs tumor progression in a murine model of advanced breast carcinoma. Int J Oncol 2017; 51:1395-1404. [PMID: 29048670 PMCID: PMC5642386 DOI: 10.3892/ijo.2017.4144] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Accepted: 07/31/2017] [Indexed: 12/12/2022] Open
Abstract
Solid tumors can generate a plethora of neurogenesis-related molecules that enhance their growth and metastasis. Among them, we have identified axonal guidance molecule Semaphorin 7A (SEMA7A) in breast cancer. The goal of this study was to determine the therapeutic effect of suppressing SEMA7A levels in the 4T1 murine model of advanced breast carcinoma. We used anti-SEMA7A short hairpin RNA (shRNA) to gene silence SEMA7A in 4T1 mammary tumor cells. When implanted into the mammary fat pads of syngeneic mice, SEMA7A shRNA-expressing 4T1 tumors exhibited decreased growth rates, deferred metastasis and reduced mortality. In vitro, SEMA7A shRNA-expressing 4T1 cells had weakened proliferative, migratory and invasive abilities, and decreased levels of mesenchymal factors. Atomic force microscopy studies showed that SEMA7A shRNA-expressing 4T1 cells had an increase in cell stiffness that corresponded with their decreased malignant potential. Genetic ablation of host-derived SEMA7A further enhanced the antitumor effects of SEMA7A shRNA gene silencing in 4T1 cells. Our preclinical findings demonstrate a critical role for SEMA7A in mediating mammary tumor progression.
Collapse
Affiliation(s)
- R Garcia-Areas
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| | - S Libreros
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| | - M Simoes
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| | - C Castro-Silva
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| | - N Gazaniga
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| | - S Amat
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| | - J Jaczewska
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| | - P Keating
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| | - K Schilling
- Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital, Boca Raton, FL 33431, USA
| | - M Brito
- Department of Pathology, Boca Raton Regional Hospital, Boca Raton, FL 33431, USA
| | - E P Wojcikiewicz
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| | - V Iragavarpu-Charyulu
- Department of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA
| |
Collapse
|
15
|
Zhang Y, Breitling LP, Balavarca Y, Holleczek B, Schöttker B, Brenner H. Comparison and combination of blood DNA methylation at smoking-associated genes and at lung cancer-related genes in prediction of lung cancer mortality. Int J Cancer 2016; 139:2482-92. [PMID: 27503000 DOI: 10.1002/ijc.30374] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 07/05/2016] [Accepted: 07/26/2016] [Indexed: 01/05/2023]
Abstract
Epigenome-wide association studies have established methylation patterns related to smoking, the major risk factor of lung cancer (LC), which are distinct from methylation profiles disclosed in LC patients. This study simultaneously investigated associations of smoking-associated and LC-related methylation markers with LC mortality. DNA methylation was determined by HM450K assay in baseline blood samples of 1,565 older adults in a population-based case-cohort study. The associations of 151 smoking-associated CpGs (smoCpGs) and 3,806 LC-related CpGs (caCpGs) with LC mortality were assessed by weighted Cox regression models, controlling for potential confounders. Multi-loci methylation scores were separately constructed based on smoCpGs and caCpGs. During a median follow-up of 13.8 years, 60 participants who had a first diagnosis of LC died from LC. The average time between sample collection and LC diagnosis was 5.8 years. Hypomethylation at 77 smoCpGs and 121 caCpGs, and hypermethylation at 4 smoCpGs and 66 caCpGs were associated with LC mortality. The associations were much stronger for smoCpGs than for caCpGs. Hazard ratios (95% CI) were 7.82 (2.91-21.00) and 2.27 (0.75-6.85), respectively, for participants in highest quartile of Score I (based on 81 smoCpGs) and Score II (based on 187 caCpGs), compared with participants in the corresponding lower three quartiles. Score I outperformed Score II, with an optimism-corrected C-index of 0.87 vs. 0.77. In conclusion, although methylation changes of both smoking-associated and LC-related genes are associated with LC mortality, only smoking-associated methylation markers predict LC mortality with high accuracy, and may thus serve as promising candidates to identify high risk populations for LC screening.
Collapse
Affiliation(s)
- Yan Zhang
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, D-69120, Germany.
| | - Lutz P Breitling
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, D-69120, Germany
| | - Yesilda Balavarca
- Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, Heidelberg, D-69120, Germany
| | | | - Ben Schöttker
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, D-69120, Germany
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, D-69120, Germany.,Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, Heidelberg, D-69120, Germany.,German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, D-69120, Germany
| |
Collapse
|